Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma

2011 ◽  
Vol 104 (10) ◽  
pp. 1544-1550 ◽  
Author(s):  
N Penel ◽  
M V Glabbeke ◽  
S Mathoulin-Pelissier ◽  
I Judson ◽  
S Sleijfer ◽  
...  
Oncology ◽  
2018 ◽  
Vol 95 (1) ◽  
pp. 1-7 ◽  
Author(s):  
Bruno Vincenzi ◽  
Giuseppe Badalamenti ◽  
Grazia Armento ◽  
Marianna Silletta ◽  
Mariella Spalato Ceruso ◽  
...  

2020 ◽  
Vol 26 (7) ◽  
pp. 1657-1666
Author(s):  
Mustafa Karaağaç ◽  
Yasin Sezgin ◽  
Melek Karakurt Eryılmaz ◽  
Murat Araz ◽  
Muhammet Ali Kaplan ◽  
...  

Introduction Soft tissue sarcomas are a heterogeneous and rare group of cancers with a short median overall survival despite the chemotherapy. Pazopanib has approval for the treatment of advanced soft tissue sarcoma. We aimed to investigate the clinical outcomes of Turkish patients with advanced soft tissue sarcoma who received pazopanib. Patients and methods This was a retrospective study. The inclusion criteria were: ≥18 years of age, having histologically proven advanced soft tissue sarcoma and receiving pazopanib at least one day. Results A total of 79 patients were assessed in this study. The median age was 49.6 years. The average dose intensity of pazopanib was 767 mg (400–800). The median duration of pazopanib treatment was 6.11 months. Fourteen patients (17.7%) used pazopanib at first line for advanced soft tissue sarcomas. The most common cause of discontinuation of pazopanib was the progression of the disease (89.6%). Pazopanib was well tolerated. The most common grade ≥3 side effect was anemia. The most common grade ≤2 side effects were anemia and hyperbilirubinemia. The median progression-free survival, overall survival, and follow-up were 3.97 months, 11.40 months, and 32.72 months, respectively. Female gender, good performance status, and the presence of pazopanib-induced hypothyroidism were associated with longer progression-free survival. Also, good performance status and being a responder to first-line treatment were associated with longer overall survival. Conclusions We showed that pazopanib was well tolerated and had clinical benefit in patients with advanced soft tissue sarcoma in a Turkish cohort. This is the first study that suggests pazopanib-induced hypothyroidism may act as a predictive marker for better outcomes in patients with advanced soft tissue sarcoma.


2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 20524-20524 ◽  
Author(s):  
D. Schoeler ◽  
A. Kunitz ◽  
P. Reichardt

20524 Background: The number of effective cytotoxic agents in treatment of advanced soft tissue sarcoma (STS) is limited when patients have failed anthracyclin and ifosfamide therapy. There are inconsistent data in phase I / II studies and retrospective analyses evaluating the efficiacy of gemcitabine (G, 900mg/m2, d1+8, q3w) or combination of gemcitabine and docetaxel (GD, G: 900mg/m2, d1+8, D: 100 mg/m2, d8, q3w). Methods: Between 2002 and 2006 we retrospectively analyzed 14 females and 6 males with heavily pretreated advanced soft tissue sarcoma (1–5 pretreatments) who were treated in our department (Charité Campus Virchow-Klinikum) with G (n=10) or GD (n=10) depending on their performance status. The following histology types were represented: leiomyosarcoma (10), liposarcoma (3), MPNST (3), synovial sarcoma (2), undifferentiated sarcoma (1), malignant large cell sarcoma (1). Results: A total of 99 cycles (range 1 to 15) were applied. Best response was partial remission (PR=20%, G: n=2, GD: n=2) and was achieved in four patients, among them three leiomyosarcoma and one MPNST. In six cases disease stabilization was achieved for up to 15 month (SD=30%, G: n=2, GD: n=4). Four patients had progressive disease after 2–3 cycles of gemcitabine based therapy (PD=20%, G: n=0, GD: n=4). In another six cases only day one of the first cycle (G alone) was administered because of serious problems due to pretreatment and poor performance status (e.g. prolonged thrombopenia and neutropenia Grade IV, gemcitabine-induced vasculitis, gastrointestinal bleeding due to tumor localization, pneumonia, rapid tumor progression). Conclusions: Gemcitabine-based therapy for heavily pretreated STS patients in our retrospective analysis has a significant overall response rate. In patients considered unfit for GD combination, single agent G treatment remains an option with moderate effiacy. No significant financial relationships to disclose.


2012 ◽  
Vol 23 ◽  
pp. ix487
Author(s):  
R. De Sanctis ◽  
A.F. Bertuzzi ◽  
P. Magnoni ◽  
L. Giordano ◽  
M. Gasco ◽  
...  

2012 ◽  
Vol 23 ◽  
pp. xi129-xi130
Author(s):  
K. Nakano ◽  
S. Takahashi ◽  
N. Nishimura ◽  
Y. Mishima ◽  
S. Sakajiri ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document